Phoenix Biotech Acquisition Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Phoenix Biotech are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Phoenix Biotech Acquisition has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Phoenix Biotech is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 507.9 K |
Phoenix |
Phoenix Biotech Relative Risk vs. Return Landscape
If you would invest (100.00) in Phoenix Biotech Acquisition on December 2, 2024 and sell it today you would earn a total of 100.00 from holding Phoenix Biotech Acquisition or generate -100.0% return on investment over 90 days. Phoenix Biotech Acquisition is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded stocks are less volatile than Phoenix, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Phoenix Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Phoenix Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Phoenix Biotech Acquisition, and traders can use it to determine the average amount a Phoenix Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PBAXU |
Based on monthly moving average Phoenix Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Phoenix Biotech by adding Phoenix Biotech to a well-diversified portfolio.
Phoenix Biotech Fundamentals Growth
Phoenix Stock prices reflect investors' perceptions of the future prospects and financial health of Phoenix Biotech, and Phoenix Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Phoenix Stock performance.
| Return On Asset | -0.0255 | |||
| Current Valuation | 66.05 M | |||
| Cash And Equivalents | 553.77 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 650 K | |||
| Book Value Per Share | (2.20) X | |||
| Cash Flow From Operations | (1.71 M) | |||
| Total Asset | 42.37 M | |||
| Retained Earnings | (10.76 M) | |||
Things to note about Phoenix Biotech Acqu performance evaluation
Checking the ongoing alerts about Phoenix Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Phoenix Biotech Acqu help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Phoenix Biotech Acqu is not yet fully synchronised with the market data | |
| Phoenix Biotech Acqu has some characteristics of a very speculative penny stock | |
| Phoenix Biotech Acqu has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Phoenix Biotech Acquisition has accumulated about 553.77 K in cash with (1.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. |
- Analyzing Phoenix Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Phoenix Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Phoenix Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Phoenix Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Phoenix Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Phoenix Biotech's stock. These opinions can provide insight into Phoenix Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |